Scientists at the renowned Francis Crick Institute in London have been using Livecyte™ to identify therapy resistant lung cancer cells, that are responsible for relapse in patients.
According to Project Research Scientist, Dr Alix Le Marois,the ability to observe factors such as cell morphology, growth and motility continuously for 6 days in a non-invasive manner has allowed her to identify unexpected behaviours related to sensitivity and resistance to treatment.
Commenting on the Livecyte software, Dr Le Marois reported that the interface was tailored for easy design of high throughput assays, accommodating multiple wells and many different conditions stating, “This is a positive aspect for me as it makes any analysis downstream much easier and also nicer to look at.”
The Crick Institute was founded in 2015 to further the understanding of the biology of health and disease and is home to 1500 scientists and support staff, making it the largest biomedical research facility in Europe.
Dr Kurt Anderson, Head of Light and Imaging Analysis who runs the Crick Advanced Microscopy facility outlined how Livecyte has allowed them to exploit live cell imaging for a wide range of applications. Citing the ability to work with unlabelled cells, segment and analyse individual cells and conduct drug studies by comparing the behaviour of large numbers of cells in 96 well plates, he added “I see a lot of potential in the future to do more sophisticated analysis of unlabelled cells, and using fluorescence in conjunction with quantitative phase microscopy, compared to what we are doing right now”.
Click Here to watch the video interview in full.